Abstract 1727P
Background
Oncology databases/cancer registries can help facilitate quality cancer care and novel research. Their maintenance remains challenging in low and middle-income countries (LMICs). We explored barriers and facilitators of oncology database maintenance in Ukraine.
Methods
We conducted semi-structured interviews with a purposeful sample of oncology physicians at the Ukraine National Cancer Institute (NCI) to explore barriers and facilitators of oncology database data entry and use. Interviews were audio-recorded, transcribed, and analyzed via hybrid analysis.
Results
13 physicians were interviewed, including 6 (46%) junior and 7 (54%) senior NCI faculty. All were aware of local or international oncology databases. 10 (77%) entered patient data into them, including 7 (54%) to international and 8 (62%) to local databases. 6 (69%) thought that most of their oncology colleagues in Ukraine are not aware of the existence or value of cancer databases. The following themes have been identified: perceived benefits of cancer databases included improving patient care, research, standardizing clinical practice, care monitoring, and quality improvement. Obstacles of data entry included: time required, low quality of medical documentation, complex online interface. Some thought that physicians should be responsible for data entry, while others thought it should be done by nonmedical providers. Facilitators of data entry included appointing a physician leader to oversee quality and engagement, direct direction from supervisor, use for research publication or as part of a project of personal interest, monetary compensation, collaborating with colleagues abroad, data entry training.
Conclusions
Factors affecting data entry into and use of local and international cancer databases by oncology physicians in Ukraine included perceived benefits for career and patient care, required time, requirements from leadership, database technology characteristics. Given limited resources for local and population-based cancer registry maintenance in Ukraine and other LMICs, novel low-cost strategies for this are urgently needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1902P - Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Presenter: Audreylie Lemelin
Session: Poster session 23
1903P - Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
Presenter: Viktor Gruenwald
Session: Poster session 23
1904P - Treatment options and outcome of metastatic renal cell carcinoma patients with brain or bone metastases: A real-world evidence from a German retrospective multi-center analysis
Presenter: Pia Paffenholz
Session: Poster session 23
1905P - Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster session 23
1906P - Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study
Presenter: Arndt Hartmann
Session: Poster session 23
1907P - Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB)
Presenter: Lisa Kinget
Session: Poster session 23
1908P - Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)
Presenter: Michael Smigelski
Session: Poster session 23
1909P - Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Presenter: Larissa Rainho
Session: Poster session 23
1910P - Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)
Presenter: Brian Rini
Session: Poster session 23
1911P - Effect of VHL mutations on efficacy of immune checkpoint inhibitors in renal cell carcinoma
Presenter: Guojie Yu
Session: Poster session 23